| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,138 | 0,179 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.11. | Oncopeptides AB: European Commission approves label expansion of Pepaxti to third-line treatment | 235 | GlobeNewswire (Europe) | STOCKHOLM - November 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally... ► Artikel lesen | |
| 05.11. | Oncopeptides AB Q3 Loss Decreases | 3 | RTTNews | ||
| 05.11. | Oncopeptides AB: Oncopeptides publishes Q3 report 2026 | 161 | GlobeNewswire (Europe) | Stockholm - November 5, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 09.10. | Oncopeptides AB: Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity study | 496 | GlobeNewswire (Europe) | STOCKHOLM - October 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing... ► Artikel lesen | |
| 17.09. | Oncopeptides AB: CHMP issues positive opinion of label expansion of Pepaxti to third-line treatment | 596 | GlobeNewswire (Europe) | STOCKHOLM - September 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for... ► Artikel lesen | |
| 27.08. | Oncopeptides Q2 2026 slides: 62% sales growth, 3rd-line expansion | 6 | Investing.com | ||
| 27.08. | Oncopeptides: Umsatz steigt im zweiten Quartal um 62 %, Aktie legt zu | 4 | Investing.com Deutsch | ||
| 27.08. | Oncopeptides AB Q2 Loss Narrows | 3 | RTTNews | ||
| ONCOPEPTIDES Aktie jetzt für 0€ handeln | |||||
| 27.08. | Oncopeptides AB: Oncopeptides publishes Q2 report 2026 | 529 | GlobeNewswire (Europe) | Stockholm - August 27, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 17.08. | Oncopeptides AB: Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe | 654 | GlobeNewswire (Europe) | STOCKHOLM - August 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Public Agency of the Republic of Slovenia... ► Artikel lesen | |
| 08.06. | Oncopeptides AB: First patient enrolled in Oncopeptides' real-world evidence study MARINA in Germany | 621 | GlobeNewswire (Europe) | STOCKHOLM - June 8, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in... ► Artikel lesen | |
| 26.05. | Oncopeptides AB: Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | 545 | GlobeNewswire (Europe) | STOCKHOLM, May 26, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has entered into an agreement with SALUS,... ► Artikel lesen | |
| 21.05. | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides | 329 | GlobeNewswire (Europe) | STOCKHOLM - May 21, 2026 - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 21 May 2026. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
| 13.05. | Oncopeptides AB: Oncopeptides publishes Q1 report 2026 | 746 | GlobeNewswire (Europe) | Stockholm - May 13, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 11.05. | Oncopeptides AB: Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment | 381 | GlobeNewswire (Europe) | STOCKHOLM - May 11, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its intention to submit a Type II variation application... ► Artikel lesen | |
| 17.03. | Oncopeptides AB: Outcome in Oncopeptides' rights issue | 466 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| 16.03. | Oncopeptides AB: Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany | 1.264 | GlobeNewswire (Europe) | STOCKHOLM - March 16, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces the initiation of the MARINA study in close... ► Artikel lesen | |
| 09.03. | Oncopeptides AB: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma | 619 | GlobeNewswire (Europe) | Stockholm, March 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that it has achieved key regulatory agreement... ► Artikel lesen | |
| 24.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.02.2026 | 432 | Xetra Newsboard | Das Instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.02.2026 und ex Kapitalmassnahme am 25.02.2026 The instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY... ► Artikel lesen | |
| 19.02. | Oncopeptides AB: Oncopeptides publishes year-end report 2025 | 454 | GlobeNewswire (Europe) | Stockholm - February 19, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2025.
"Oncopeptides... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,60 | -0,07 % | Option auf Zeitgewinn: BioNTech investiert Millionen in möglichen Zulassungsvorsprung | Mit einem Prüfungsgutschein will BioNTech die Entscheidung der US-Arzneimittelbehörde über ein Krebsmedikament um rund vier Monate vorziehen. Damit wären frühere Umsätze möglich, doch Studienrückschläge... ► Artikel lesen | |
| EVOTEC | 2,728 | -0,80 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 179,14 | -4,73 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| AMGEN | 405,10 | -2,64 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| VALNEVA | 2,411 | -6,59 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| NOVAVAX | 7,180 | -0,69 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| STRYKER | 290,10 | +0,52 % | Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements-and he won't build them in China because 'the IP is a massive worry' | ||
| BIOGEN | 227,05 | -0,39 % | Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's Disease | WESTON (dpa-AFX) - Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with... ► Artikel lesen | |
| BIOFRONTERA | 2,820 | -3,75 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| HEIDELBERG PHARMA | 2,010 | -1,47 % | Formycon, Heidelberg Pharma und Medios: Drei Biotech-Nebenwerte, drei völlig unterschiedliche Signale - Formycon hat die Analysten auf seiner Seite | ||
| ILLUMINA | 191,14 | +3,82 % | Illumina Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| SUMMIT THERAPEUTICS | 10,500 | -1,59 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| CG ONCOLOGY | 80,01 | 0,00 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an |